Balancing the risks of stent thrombosis andmajor bleeding during primary percutaneous coronary intervention

European Heart Journal

Volumn 35, Issue 36, 2014, Pages 2448-2451

  Gutierrez, Antonio ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; TICAGRELOR; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ANGIOGRAPHY; DEATH; DRUG ELUTING STENT; DRUG USE; EDITORIAL; HEART DEATH; HUMAN; MONOTHERAPY; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; MYOCARDIAL INFARCTION; PROCEDURES;

ANTICOAGULANTS; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS;

EID: 84929940627     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu223     Document Type: Editorial

References (16)

1. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008;371:2134-2143.
2. Kumbhani DJ, Bhatt DL. Platelet activation: yet another strike against routine TRANSFUSION. Eur Heart J 2010;31:2712-2714.
3. Zeymer U, van't Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, Steg PG. Bivalirudin is superior to heparins alone with bailout GPIIb/IIIa Inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J 2014;35:2460-2467.
4. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230.
5. StegPG, van'tHof A,HammCW,Clemmensen P, Lapostolle F,CosteP,Ten Berg J,Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-2217.
6. Shahzad A, Stables R. How effective are antithrombotic therapies in PPCI (HEAT-PPCI). In: Cardiosource Abstracts Published as J Am Coll Cardiol., Vol. 63, no. 12-S, 29-31 March 2014. American College of Cardiology,Washington, DC.
7. Steg PG,MehranR,Goldstein P,Witzenbicher B, van'tHofA,GuagliumiG,HammCW, Genereux P, Clemmensen P, Parise H, Pocock S, Gersh B, Bernstein D, Deliargyris EN, Stone GW; Bivalirudin vs. heparin, with or without glycoprotein IIb/IIIa inhibitors in STEMI patients undergoing primary PCI: a pooled analysis of patient-level data from the HORIZONS-AMI and EUROMAX trials. In: Cardiosource Abstracts Published as J Am Coll Cardiol., Vol. 63, no. 12-S, 29-31March 2014. American College of Cardiology, Washington, DC.
8. Chew DP, Bhatt DL, Lincoff AM,Wolski K, Topol EJ. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart 2006;92:945-950.
9. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
10. StoneGW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.
11. Bangalore S, Pencina MJ, Kleiman NS, Cohen DJ. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-st-segment-elevation acute coronary syndromes or stable ischemic heart disease: results fromthe evaluation of drug-eluting stents and ischemic events registry. Circ Cardiovasc Interv 2014;63: 619-629.
12. Clemmensen P, van't Hof A, Deliargyris EN, Coste P, ten Berg J, Cavallini C, Hamon M, Dudek D, Zeymer U, Tabone X, Clayton T, Bernstein D, Prats J; Predictors associated with acute stent thrombosis after primary PCI: the EUROMAX TRIAL. In: Cardiosource Abstracts Published as J Am Coll Cardiol., Vol. 63, no. 12-S, 29-31 March 2014. American College of Cardiology,Washington, DC.
13. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, WidimskýP, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, WhiteHD, HarringtonRA;CHAMPIONPHOENIXInvestigators. Effectof platelet inhibition with cangrelor during PCI on ischemic events.N Engl JMed 2013;368:1303-1313.
14. Genereux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014;63: 619-629.
15. Steg PG, Bhatt DL, Hamm CW, StoneGW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA; CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-1992.
16. White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA; Reduced death, myocardial infarction, and early stent thrombosis with cangrelor versus clopidogrel on a background of bivalirudin: Insights from CHAMPION PHOENIX. In: Cardiosource Abstracts Published as J Am Coll Cardiol., Vol. 63, no. 12-S, 29-31 March 2014. American College of Cardiology,Washington, DC.